ArticlePDF Available

Abstract and Figures

Ovarian insufficiency is a major long-term adverse event, following the administration of a myeloablative conditioning regimen, and occurring in >80% of children and adolescents receiving such treatment for malignant or non-malignant disease. Cryopreservation of ovarian tissue is currently offered to preserve the fertility of these young patients. At least 35 live births have been reported after transplantation of cryopreserved ovarian tissue in adult patients, but the procedure remains unproven for ovarian tissue harvested at a prepubertal or pubertal age. We report here the first live birth after autograft of cryopreserved ovarian tissue in a woman with primary ovarian failure after a myeloablative conditioning regimen as part of a hematopoietic stem cell transplantation performed for homozygous sickle-cell anemia at age 14 years. This first report of successful fertility restoration after the graft of ovarian tissue cryopreserved before menarche offers reassuring evidence for the feasibility of the procedure when performed during childhood. © The Author 2015. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Content may be subject to copyright.
CASE REPORT Infertility
Live birth after autograft of ovarian
tissue cryopreserved during childhood
Isabelle Demeestere
1,2,
*
, Philippe Simon
3
, Laurence Dedeken
4
,
Federica Moffa
1,6
, Sophie Tse
´
pe
´
lidis
1,2,7
, Cecile Brachet
5
,
Anne Delbaere
1,2
, Fabienne Devreker
1,5
, and Alina Ferster
4
1
Research Laboratory on Human Reproduction, Faculty of Medicine, Universite
´
Libre de Bruxelles (ULB), Campus Erasme, CP636, 808 route de
Lennik, 1070 Brussels, Belgium
2
Fertility Clinic, Department of Obstetrics and Gynaecology, Erasme Hospital, Universite
´
Libre de Bruxelles,
1070 Brussels, Belgium
3
Gynecology Clinic, Department of Obstetrics and Gynaecology, Erasme Hospital, Universite
´
Libre de Bruxelles (ULB),
1070 Brussels, Belgium
4
Department of Hematology-Oncology, Ho
ˆ
pital Universitaire des Enfants Reine Fabiola (HUDERF), 1020 Brussels,
Belgium
5
Department of Endocrinology, Ho
ˆ
pital Universitaire des Enfants Reine Fabiola (HUDERF), 1020 Brussels, Belgium
6
Present address: Instituto Marque
´
s, Assisted Reproduction Service, Manuel Girona 33, MASIA, 08034 Barcelona, Spain
7
Present address: Nivelles Hospital, Rue Samiette, 1400 Nivelles, Belgium
*Correspondence address. Tel: +32-2-5556358; E-mail: idemeest@ulb.ac.be
Submitted on April 3, 2015; resubmitted on May 7, 2015; accepted on May 14, 2015
abstract: Ovarian insufficiency is a major long-term adverse event, following the administration of a myeloablative conditioning regimen,
and occurring in .80% of children and adolescents receiving such treatment for malignant or non-malignant disease. Cryopreservation of ovarian
tissue is currently offered to preserve the fertility of these young patients. At least 35 live births have been reported after transplantation of
cryopreserved ovarian tissue in adult patients, but the procedure remains unproven for ovarian tissue harvested at a prepubertal or pubertal
age. We report here the first live birth after autograft of cryopreserved ovarian tissue in a woman with primary ovarian failure after a myeloablative
conditioning regimen as part of a hematopoietic stem cell transplantation performed for homozygous sickle-cell anemia at age 14 years. This first
report of successful fertility restoration afterthe graft of ovarian tissue cryopreserved before menarche offers reassuringevidence for the feasibility
of the procedure when performed during childhood.
Key words: fertility preservation / childhood / ovarian tissue cryopreservation / transplantation / live birth
Introduction
Long-term survivors of hematological diseases diagnosed during
childhood are increasing in number, owing to improvements in treat-
ments and supportive care. Hematopoi etic stem cell transplanta-
tion (HSCT) is now offered as curative therapy for a wide v ariety of
malignant and non-malignant hematological disorders. However, the
risk of subfertility and premature ovarian insufficiency (POI) following
HSCT exceeds 80% in childhood cancer survivors, including teenagers
(Brougham and Wallace, 2005; Borgmann-Staudt et al., 2012). For
prepubertal female patients who face a high risk of treatment-induced
POI, the only option available to preserve fertility is the cryopreserva-
tion of ovarian tissue (Demeestere et al.,2009; Imbert et al., 2014;
Wallace et al., 2014). However, the successful outcome of this ap-
proach has been demonstrated only in pat ients who were adults at
thetimeoftheirdiagnosis(Stoop et al., 2014; Donnez et al., 2015).
As yet, the efficacy of the procedure in children has remained
unproven.
Case Report
We report the case of a woman aged 27 years, who was born in the
Republic of Congo and diagnosed with sickle-cell anemia at the age of
5, having experienced several episodes of fever and severe anemia.
Having emigrated to Belgium at the age of 11, her initial medical
work-up revealed abnormal blood flow velocities on a transcranial
Doppler echography. Subsequent treatment with hydroxyurea was
initiated. Due to her significant disease severity, curative therapy with
HSCT, made possible with the availability of a matched sibling donor,
was required. The option of ovarian tissue cryopreservation to preserve
fertility was offered and explained to both parents and child prior to the
initiation of the conditioning regimen. The parents signed the written
consent form. She had reportedly started puberty (breast development)
at around 10 years of age and her hormonal profile showed follicle-
stimulating hormone [FSH], luteinizing hormone [LH] and estradiol
levels of 6.3, 2.9 IU/l and 28 pg/ml, respectively, in October 2000. At
the time of the ovarian tissue cryopreservation procedure, she was
& The Author 2015. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
Human Reproduction, Vol.30, No.9 pp. 21072109, 2015
Advanced Access publication on June 9, 2015 doi:10.1093/humrep/dev128
by guest on August 21, 2015http://humrep.oxfordjournals.org/Downloaded from
aged 13 years and 11 months (height 158 cm and weight 37 kg), and had
never experienced menstruation. A right oophorectomy was carried out
by laparoscopy in June 2001, and 62 fragments of ovarian tissue (2 ×
3 × 1 2 mm) were cryopreserved, as previously described (Demees-
tere et al., 2006). The conditioning regimen consisted of oral busulfan
(16 mg/kg), cyclophosphamide (200 mg/kg) and anti-thymocyte globu-
lin (ATG 12 mg/kg), and graft-versus-host disease (GVHD) prophylaxis
with cyclosporin and methotrexate. Following HSCT, the patient devel-
oped grade II acute GVHD, and also limited chronic GVHD that required
the continuation of immunosuppressive drugs for 18 months. All hema-
tological values, as well as cerebral velocities, were normalized after
HSCT, and full donor chimerism was obtained. As expected, following
myeloablative conditioning, the patient developed primary ovarian
failure, with elevated gonadotropins. Menarche was induced at the age
of 15.5 years (Tanner stage A2P3M3) with the use of a third-generation
estrogenprogesterone preparation.
Ten years later, the patient was counseled for her wish to become
pregnant. After the interruption of hormonal supplementation, POI
was confirmed by the presence of permanent amenorrhea and high go-
nadotropin levels (FSH 59 IU/l, LH 32 IU/l). The patient underwent
ovarian tissue transplantation, in order to restore her fertility. Prior to
transplantation, two fragments of ovarian tissue were thawed for follicu-
lar density assessment. Two and six follicles per millimeter square were
observed in the fragments. Transplantation was performed by atwo-step
laparoscopy procedure (Demeestere et al., 2006), using a da Vinci surgi-
cal robotic system in May 2011. Four thawed ovarian fragments were
grafted on the residual left ovary, six were grafted in the right peritoneal
bursa, and five were grafted subcutaneously using a trocar incision.
Following the grafting procedure, the FSH level progressively
decreased, whereas both inhibin B and estradiol serum levels increased
(Fig. 1). Four months later, the hormonal levels reached the premeno-
pausal range (FSH 5 IU/l; LH 6 U/l; estradiol E2 166 pg/ml), and
ovarian activity wasobserved in all transplanted sites on pelvic ultrasound
imaging. Menstruation was first occurred 5 months post-transplantation
of ovarian tissue and was followed by regular menstrual cycles thereafter.
The patient had recourse to assisted reproductive technologies for
male infertility, although all such treatments were discontinued due
to relationship issues. Although she did not conceive during the first
2 years post-transplantation, she reported regular menstruation
throughout this period. Basal FSH levels remained within the normal
range throughout most of the menstrual cycles (Fig. 1), while anti-
Mu
¨
llerian hormone (AMH) levels remained undetectable. After more
than two years post-transplantation,the patient had a spontaneous preg-
nancy with a new partner and spontaneously delivered a healthy boy in
November 2014 (birthweight 3140 g, Apgar score of 9 and 10 at 1 and
5 min, respectively).
Ethical approval
The procedures were approved by ethical committees of the Erasme
Hospital and of the Ho
ˆ
pital Universitaire des Enfants Reine Fabiola
(Brussels, Belgium).
Discussion
This case reports the first live birth after transplantation of ovarian tissue
harvested before menarche. To our knowledge, only two cases of
cryopreserved ovarian tissue autograft, with the aim of inducing
puberty, have been reported in children (Poirot et al., 2012; Ernst
et al., 2013); in each case, ovarian function was restored for at least 19
months and puberty was successfully induced. While the use of an ex-
perimental and invasive procedure for this clinical indication raises a
number of concerns (Anderson et al., 2013), the authors showed, for
the first time, the possibility of restoring endocrine function from
Figure 1 FSH and estradiol levels before and after autograft of cryopreserved ovarian tissue. The autograft procedure is represented at time 0 months.
The arrow indicates the first menstruation.
2108 Demeestere et al.
by guest on August 21, 2015http://humrep.oxfordjournals.org/Downloaded from
ovarian tissue harvested before puberty (Poirot et al., 2012; Ernst et al.,
2013). The prepubertal ovary contains many follicles at an early stage of
development, which is theoretically favorable for restoring ovarian func-
tion after grafting. However, the developmental competence of these
oocytes remains poorly investigated. Immature oocytes collected from
prepubertal ovarian tissue have been shown to mature in vitro, but to a
lesser degree than those retrieved from adult tissue (Revel et al., 2009;
Fasano et al., 2011). A recent studyreported that ovarian tissue frompre-
pubertal girls contains a larger proportion of abnormal follicles, compared
with adult ovarian tissue, and in vitro activation of quiescent follicles also
occurs differently, leading to limited follicular development (Anderson
etal.,2014). Thesedatahighlighttheneed tofurtherinvestigatethe viability
of ovarian tissuetransplantationfor restoring fertilitywhenthe cryopreser-
vation procedure occurs before the patient starts puberty.
While cryopreservation of ovarian tissue is a common procedure to
preserve fertility in children, this report offers, for the first time, evidence
for the long-term survival of autografts of ovarian tissue cryopreserved
before menarche and the efficiency of the procedure to restore fertility.
Acknowledgement
We thank J. Dechene for her contribution to the fertility preservation
program.
Authors’ roles
I.D. was responsible for the fertility preservation program and per-
formed the cryopreservation procedure. I.D. and L.D. contributed to
the data collection and analysis and wrote the manuscript. A.F. contrib-
uted to the data collection and analysis, performed the HSCT, referred
the patient for fertility preservationand revised the manuscript. C.B. con-
tributed to the data collection and manuscript revision. P.S. performed
the ovarian tissue transplantation procedure. F.M. and S.T. managed
the patient during the transplantation and the follow up. A.D. and F.D.
contributed to the development of the fertility preservation pro-
gram, managed the patient for assisted reproductive treatments and
contributed to the revision of the manuscript.
Funding
This program was supported by the Fondation Belge contre le Cancer
and the Fonds de la Recherche Scientifique FNRS-Te
´
le
´
vie. I.D. is a
research associate at the FNRS.
Conflict of interest
None declared.
References
Anderson RA, Hindmarsh PC, Wallace WH. Induction of puberty by
autograft of cryopreserved ovarian tissue in a patient previously treated
for Ewing sarcoma. Eur J Cancer 2013;49:2960 2961.
Anderson RA, McLaughlin M, Wallace WH, Albertini DF, Telfer EE. The
immature human ovary shows loss of abnormal follicles and increasing
follicle developmental competence through childhood and adolescence.
Hum Reprod 2014;29:97 106.
Borgmann-Staudt A, Rendtorff R, Reinmuth S, Hohmann C, Keil T,
Schuster FR, Holter W, Ehlert K, Keslova P, Lawitschka A et al. Fertility
after allogeneic haematopoietic stem cell transplantation in childhood
and adolescence. Bone Marrow Transplant 2012;47:271 276.
Brougham MF, Wallace WH. Subfertility in childrenand young people treated
for solid and haematological malignancies. Br J Haematol 2005;131:
143155.
Demeestere I, Simon P, Buxant F, Robin V, Fernandez SA, Centner J,
Delbaere A, Englert Y. Ovarian function and spontaneous pregnancy
after combined heterotopic and orthotopic cryopreserved ovarian
tissue transplantation in a patient previously treated with bone marrow
transplantation: case report. Hum Reprod 2006;21:2010 2014.
Demeestere I, Simon P, Emiliani S, Delbaere A, Englert Y. Orthotopic and
heterotopic ovarian tissue transplantation. Hum Reprod Update 2009;
15:649665.
Donnez J, Dolmans MM, Pellicer A, Diaz-Garcia C, Ernst E, Macklon KT,
Andersen CY. Fertility preservation for age-related fertility decline.
Lancet 2015;385:506 507.
Ernst E, Kjaersgaard M, Birkebaek NH, Clausen N, Andersen CY. Case
report: stimulation of puberty in a girl with chemo- and radiation therapy
induced ovarian failure by transplantation of a small part of her frozen/
thawed ovarian tissue. Eur J Cancer 2013;49:911914.
Fasano G, Moffa F, Dechene J, Englert Y, Demeestere I. Vitrification of in vitro
matured oocytes collected from antral follicles at the time of ovarian tissue
cryopreservation. Reprod Biol Endocrinol 2011;9:150.
Imbert R, Moffa F, Tsepelidis S, Simon P, Delbaere A, Devreker F, Dechene J,
Ferster A, Veys I, Fastrez M et al. Safety and usefulness of cryopreservation
of ovarian tissue to preserve fertility: a 12-year retrospective analysis. Hum
Reprod 2014;29:19311940.
Poirot C, Abirached F, Prades M, Coussieu C, Bernaudin F, Piver P. Induction
of puberty by autograft of cryopreserved ovarian tissue. Lancet 2012;
379:588.
Revel A, Revel-Vilk S, Aizenman E, Porat-Katz A, Safran A, Ben-Meir A,
Weintraub M, Shapira M, Achache H, Laufer N. At what age can human
oocytes be obtained? Fertil Steril 2009;92:458463.
Stoop D, Cobo A, Silber S. Fertility preservation for age-related fertility
decline. Lancet 2014;384:1311 1319.
Wallace WH, Smith AG, Kelsey TW, Edgar AE, Anderson RA. Fertility
preservation for girls and young women with cancer: population-based
validation of criteria for ovarian tissue cryopreservation. Lancet Oncol
2014;15:11291136.
Graft of ovarian tissue harvested during childhood 2109
by guest on August 21, 2015http://humrep.oxfordjournals.org/Downloaded from
... Cryopreservation of oocytes [2], embryos [3], or ovarian tissue [4] is considered to be the standard method for FP. Although these techniques have been proven to be effective, they are invasive and have limitations such as the risk of reinsertion of cancer cells after transplantation of cryopreserved ovarian tissue, the only option available for pre-pubertal cancer patients [5]. ...
Article
Full-text available
Although effective in terms of the chances of future live birth, the current methods for fertility preservation, such as oocyte, embryo, or ovarian tissue cryopreservation, cannot be offered to all cancer patients in all clinical contexts. Expanding options for fertility preservation is crucial to addressing the need to encompass all situations. One emerging strategy is pharmacoprotection, a non-invasive approach that has the potential to fill existing gaps in fertility preservation. In addition to the identification of the most effective therapeutic agents, the potential for off-target effects remains one of the main limitations of this strategy for clinical application, particularly when healthy ovarian tissue is targeted. This review focuses on the advances in pharmacoprotective approaches and the challenge of targeting the ovaries to deliver these agents. The unique properties of gold nanoparticles (AuNPs) make them an attractive candidate for this purpose. We discuss how AuNPs meet many of the requirements for an ideal drug delivery system, as well as the existing limitations that have hindered the progression of AuNP research into more clinical trials. Additionally, the review highlights microRNA (miRNA) therapy as a next-generation approach to address the issues of fertility preservation and discusses the obstacles that currently impede its clinical availability.
... Cryopreservation of oocytes [2], embryos [3], or ovarian tissue [4] are considered as the standard methods for FP. Although these techniques have been proven efficiency for women undergoing the procedure, they are invasive and have limitations such as the risk of reinsertion of cancer cells after transplantation of cryopreserved ovarian tissue, which remains the only option for pre-pubertal cancer patients [5]. ...
Preprint
Full-text available
Although effective in term of chance of future live birth, the current methods for fertility preservation such as oocytes, embryo or ovarian tissue cryopreservation cannot be offered to all cancer patients and in all clinical contexts. Expanding options for fertility preservation is crucial to address the need to encompass all situations. One emerging strategy is pharmacoprotection, which is non-invasive and has the potential to fill existing gaps in fertility preservation. Besides the identification of the most efficient therapeutic agent itself, the potential off-target effect re-mains one of the main limitation of this strategy for clinical application, particularly when healthy ovarian tissue is targeted. This review focuses on the advances in pharmacoprotective approaches and the challenge of targeting the ovaries to deliver these agents. The unique properties of gold nanoparticles (AuNPs) make them an attractive candidate for this purpose. We discuss how AuNPs meet many of the requirements for an ideal drug delivery system, as well as the existing limitations that have hindering the progression of AuNPs research into more clinical trials. Additionally, the review highlights microRNA (miRNA) therapy as a next-generation approach to address the issues of fertility preservation and discusses the obstacles that currently impede its clinical availability.
... However, ovarian tissue transplantation (OTT) is still considered experimental. In girls for whom transvaginal procedures are not an option due to their prepubertal status or discomfort with the procedure, OTC is preferable over oocyte cryopreservation as a fertility preservation option [7,8]; however, only two cases of live births resulting from OTC and OTT have been reported in patients who underwent OTC before menarche (at the ages of 9 and 13 years) [9,10]. ...
Article
Full-text available
Although recent in vitro maturation (IVM) studies in pediatric patients have demonstrated successful retrieval and maturation of oocytes, the studies included only a small number of premenarchal patients. In the present study, we examined the potential use of oocyte retrieval and maturation for pediatric patients who undergo ovarian tissue cryopreservation (OTC). We retrospectively examined the clinical records of pediatric patients who underwent OTC at our institution between October 2015 and December 2022. Data on the age, primary disease, menstrual history, pre-procedure chemotherapy, anti-Müllerian hormone (AMH) level, number of oocytes collected ex vivo from ovarian tissue, and number of mature oocytes from IVM were examined. Data of 60 pediatric patients (aged 1 to 17 years) were included for analysis. Oocytes were retrieved from 36 patients; the oocytes of 18 of these patients could be cryopreserved. The IVM rate was significantly lower in the premenarchal patients than in the postmenarchal patients. The number of mature oocytes retrieved from IVM was higher in the no-chemotherapy group than in the chemotherapy group. A significant positive correlation was observed between the AMH level and the IVM outcomes. Oocyte retrieval and maturation in pediatric patients undergoing OTC is particularly useful in those not receiving chemotherapy. In patients receiving chemotherapy, the AMH level may be useful for predicting the IVM outcome. Activation of the oocyte maturation process in vivo in pediatric patients and better understanding of the major regulators of oocyte maturation are necessary to improve the utility of the IVM procedure.
... It is estimated that around 200 live births were achieved in 2020 from the transplanted ovarian tissue cryopreserved for FP purposes. However, only two cases of live births have been reported in patients who underwent OTC before menarche [70,79,80]. Therefore, most experts agree that procedures should be performed within the clinical studies protocols, and outcomes should be carefully followed. ...
Article
Full-text available
Oncofertility is any therapeutic intervention to safeguard the fertility of cancer patients. Anti-cancer therapies (chemotherapy, radiation therapy, etc.) entail the risk of reproductive disorders through cytotoxic effects on gamete-building cells, especially those not yet fully developed. This literature review analyzes the available data on securing fertility in pediatric and adolescent populations to identify the methods used and describe aspects related to financing, ethics, and the perspective of patients and their parents. Topics related to oncofertility in this age group are relatively niche, with few peer-reviewed articles available and published studies mostly on adults. Compared to pubertal individuals, a limited number of fertility preservation methods are used for prepubertal patients. Funding for the procedures described varies from country to country, but only a few governments choose to reimburse them. Oncofertility of pediatric and adolescent patients raises many controversies related to the decision, parents’ beliefs, having a partner, ethics, as well as the knowledge and experience of healthcare professionals. As the fertility of young cancer patients is at risk, healthcare professionals should make every effort to provide them with an opportunity to fulfill their future reproductive plans and to have a family and offspring. Systemic solutions should form the basis for the development of oncofertility in pediatric and adolescent populations.
Article
In the USA, one child in 285 children is diagnosed with cancer every year, but thanks to improvements in medicine, the survival rate has reached 80%. However, cancer treatments, such as chemotherapy and radiation, are likely to affect their fertility later in life, limiting their ability to conceive. To reduce this risk, ovarian tissue cryopreservation is a surgical procedure that allows the ovarian tissue to be retrieved and cryopreserved in order to be reimplanted back into the abdomen and restore ovarian function in children who become infertile due to gonadotoxic treatments. A case study published in 2014 offered recommendations to help assess whether such a procedure should be offered to female patients who have not yet entered puberty. This paper will investigate whether, in light of more recent and updated literature, their recommendations may need to be revised.
Article
Adolescent and young adult (AYA) oncology patients are unique in many aspects of their care; fertility preservation (FP) is one of the most complex to address. In addition to the newly diagnosed AYA patient, there are growing numbers of AYA survivors of childhood cancer who present with concerns about their fertility. Emerging independence, emotional and intellectual growth, and development of an adult mindset are hallmarks of the AYA population; these transitions heighten the intrinsic medical, social, and financial challenges of a cancer diagnosis. FP is extraordinarily important in AYA oncology and can be addressed in many ways: experimental options as well as standard of care, with key differences on the basis of pubertal development, cancer diagnosis, and urgency of cancer-directed therapy. Options exist both at diagnosis and throughout the survivorship journey. It is imperative that oncologists recognize the challenges in this age group, as well as opportunities to pursue FP. The field has evolved significantly in the past 25 years and will continue to evolve as we incorporate more immune-based and targeted therapies into our treatment regimens. This case-based review will explore opportunities to preserve fertility in this unique patient population.
Article
Introduction: Hematopoietic stem cell transplant (HSCT) is the only readily available curative option for sickle cell disease (SCD). Cure rates following human leukocyte antigen (HLA)-matched related donor HSCT with myeloablative or non-myeloablative conditioning are >90%. Alternative donor sources, including haploidentical donor and autologous with gene therapy, expand donor options but are limited by inferior outcomes, limited data, and/or shorter follow-up and therefore remain experimental. Areas covered: Outcomes are improving with time, with donor type and conditioning regimens having the greatest impact on long-term complications. Patients with stable donor engraftment do not experience SCD-related symptoms and have stabilization or improvement of end-organ pathology; however, the long-term effects of curative strategies remain to be fully established and have significant implications in a patient's decision to seek therapy. This review covers currently published literature on HSCT outcomes, including organ-specific outcomes implicated in SCD, as well as long-term effects. Expert opinion: HSCT, both allogeneic and autologous gene therapy, in the SCD population reverses the sickle phenotype, prevents further organ damage, can resolve prior organ dysfunction in both pediatric and adult patients. Data support greater success with HSCT at a younger age, thus, curative therapies should be discussed early in the patient's life.
Article
Full-text available
Over the past two decades, the importance of fertility preservation has grown not only in the realm of medical and clinical patient care, but also in the field of basic and applied research in human reproduction. With advancements in cancer treatments resulting in higher rates of patient survival, it is crucial to consider the quality of life post-cure. Therefore, fertility preservation must be taken into account prior to antitumor treatments, as it can significantly impact a patient’s future fertility. For postpubertal patients, gamete cryopreservation is the most commonly employed preservation strategy. However, for prepubertal patients, the situation is more intricate. Presently, ovarian tissue cryopreservation is the standard practice for prepubertal girls, but further scientific evidence is required in several aspects. Testicular tissue cryopreservation, on the other hand, is still experimental for prepubertal boys. The primary aim of this review is to address the strategies available for possible fertility preservation in prepubertal girls and boys, such as ovarian cryopreservation/transplantation, in vitro follicle culture and meiotic maturation, artificial ovary, transplantation of cryopreserved spermatogonia, and cryopreservation/grafting of immature testicular tissue and testicular organoids.
Article
Full-text available
Background: Ovarian tissue cryopreservation with later reimplantation has been shown to preserve fertility in adult women, but this approach remains unproven and experimental in children and adolescents. We aimed to assess the use of the Edinburgh selection criteria for ovarian tissue cryopreservation in girls and young women with cancer to determine whether we are offering this invasive procedure to the patients who are most at risk of premature ovarian insufficiency. Methods: Cryopreservation of ovarian tissue has been selectively offered to girls and young women with cancer who met the Edinburgh selection criteria since 1996. Between Jan 1, 1996, and June 30, 2012, 410 female patients younger than 18 years at diagnosis were treated for cancer (including leukaemia and brain tumours) at the Edinburgh Children's Cancer Centre, which serves the whole South East of Scotland region. We determined the ovarian status of these patients from review of clinical records and classified them as having premature ovarian insufficiency or not, or as unable to be determined. Patients younger than 12 years at time of data cutoff (Jan 31, 2013) were excluded from the analysis. Findings: 34 (8%) of the 410 patients met the Edinburgh selection criteria and were offered ovarian tissue cryo-preservation before starting cancer treatment. 13 patients declined the procedure and 21 consented, and the procedure was completed successfully in 20 patients. Of the 20 patients who had ovarian tissue successfully cryopreserved, 14 were available for assessment of ovarian function. Of the 13 patients who had declined the procedure, six were available for assessment of ovarian function. Median age at the time of follow-up for the 20 assessable patients was 16·9 years (IQR 15·5–21·8). Of the 14 assessable patients who had successfully undergone ovarian cryopreservation, six had developed premature ovarian insufficiency at a median age of 13·4 years (IQR 12·5–14·6), one of whom also had a natural pregnancy. Of the six assessable patients who had declined the procedure, one had developed premature ovarian insuffi ciency. Assessment of ovarian function was possible for 141 of the 376 patients who were not off ered cryopreservation; one of these patients had developed premature ovarian insuffi ciency. The cumulative probability of developing premature ovarian insufficiency after treatment was completed was significantly higher for patients who met the criteria for ovarian tissue cryopreservation than for those who did not (15-year probability 35% [95% CI 10–53] vs 1% [0–2]; p<0·0001; hazard ratio 56·8 [95% CI 6·2–521·6] at 10 years). Interpretation: The results of this analysis show that the Edinburgh selection criteria accurately identify the few girls and young women who will develop premature ovarian insufficiency, and validate their use for selection of patients for ovarian tissue cryopreservation. Further follow-up of this cohort of patients is likely to allow refinement of the criteria for this experimental procedure in girls and young women with cancer.
Article
Full-text available
STUDY QUESTION Do the benefits of ovarian tissue cryopreservation outweigh the risks for patients seeking to preserve fertility before gonadotoxic treatment in various indications?
Article
Full-text available
Do the ovarian follicles of children and adolescents differ in their morphology and in vitro growth potential from those of adults? Pre-pubertal ovaries contained a high proportion of morphologically abnormal non-growing follicles, and follicles showed reduced capacity for in vitro growth. The pre-pubertal ovary is known to contain follicles at the early growing stages. How this changes over childhood and through puberty is unknown, and there are no previous data on the in vitro growth potential of follicles from pre-pubertal and pubertal girls. Ovarian biopsies from five pre-pubertal and seven pubertal girls and 19 adult women were analysed histologically, cultured in vitro for 6 days, with growing follicles then isolated and cultured for a further 6 days. Ovarian biopsies were obtained from girls undergoing ovarian tissue cryopreservation for fertility preservation, and compared with biopsies from adult women. Follicle stage and morphology were classified. After 6 days in culture, follicle growth initiation was assessed. The growth of isolated secondary follicles was assessed over a further 6 days, including analysis of oocyte growth. Pre-pubertal ovaries contained a high proportion of abnormal non-growing follicles (19.4 versus 4.85% in pubertal ovaries; 4004 follicles analysed; P = 0.02) characterized by indistinct germinal vesicle membrane and absent nucleolus. Follicles with this abnormal morphology were not seen in the adult ovary. During 6 days culture, follicle growth initiation was observed at all ages; in pre-pubertal samples there was very little development to secondary stages, while pubertal samples showed similar growth activation to that seen in adult tissue (pubertal group: P = 0.02 versus pre-pubertal, ns versus adult). Isolated secondary follicles were cultured for a further 6 days. Those from pre-pubertal ovary showed limited growth (P < 0.05 versus both pubertal and adult follicles) and no change in oocyte diameter over that period. Follicles from pubertal ovaries showed increased growth; this was still reduced compared with follicles from adult women (P < 0.05) but oocyte growth was proportionate to follicle size. These data derive from only a small number of ovarian biopsies, although large numbers of follicles were analysed. It is unclear whether the differences between groups are related to puberty, or just age. These findings show that follicles from girls of all ages can be induced to grow in vitro, which has important implications for some patients who are at high risk of malignant contamination of their ovarian tissue. The reduced growth of isolated follicles indicates that there are true intrafollicular differences in addition to potential differences in their local environment, and that there are maturational processes occurring in the ovary through childhood and adolescence, which involve the loss of abnormal follicles, and increasing follicle developmental competence. Funded by MRC grants G0901839 and G1100357. No competing interests.
Article
Full-text available
In the past few years, cryopreservation of ovarian tissue has become an established procedure proposed in many centers around the world and transplantation has successfully resulted in full-term pregnancies and deliveries in human. This prospective study aims to evaluate the feasibility of vitrifying in vitro matured oocytes (IVM) isolated at the time of ovarian tissue cryopreservation to improve the efficiency of fertility preservation programs. Oocyte-cumulus complexes were retrieved from freshly collected ovarian cortex by aspirating antral follicular fluid, and were matured in vitro for 24-48 h prior to vitrification. Oocytes were matured in an IVM commercial medium (Copper Surgical, USA) supplemented with 75 mIU/ml FSH and 75 mIU/ml LH and vitrified using a commercial vitrification kit (Irvine Scientific, California) in high security vitrification straws (CryoBioSystem, France). Oocyte collection and IVM rates were evaluated according to the age, the cycle period and the amount of tissue collected. Immature oocyte retrieval from ovarian tissue was carried out in 57 patients between 8 and 35 years of age, undergoing ovarian tissue cryopreservation. A total of 266 oocytes were isolated, 28 of them were degenerated, 200 were at germinal vesicle stage (GV), 35 were in metaphase I (MI) and 3 displayed a visible polar body (MII). The number of oocytes collected was positively correlated with the amount of tissue cryopreserved (p < 0.001) and negatively correlated with the age of the patients (p = 0.005). Oocytes were obtained regardless of menstrual cycle period or contraception. A total maturation rate of 31% was achieved, leading to the vitrification of at least one mature oocyte for half of the cohort. The study showed that a significant number of immature oocytes can be collected from excised ovarian tissue whatever the menstrual cycle phases and the age of the patients, even for prepubertal girls.
Article
Cryopreservation of eggs or ovarian tissue to preserve fertility for patients with cancer has been studied since 1994 with R G Gosden's paper describing restoration of fertility in oophorectomised sheep, and for decades previously by others in smaller mammals. Clinically this approach has shown great success. Many healthy children have been born from eggs cryopreserved with the Kuwayama egg vitrification technique for non-medical (social) indications, but until now very few patients with cancer have achieved pregnancy with cryopreserved eggs. Often, oncologists do not wish to delay cancer treatment while the patient goes through multiple ovarian stimulation cycles to retrieve eggs, and the patient can only start using the oocytes after full recovery from cancer. Ovarian stimulation and egg retrieval is not a barrier for patients without cancer who wish to delay childbearing, which makes oocyte cryopreservation increasingly popular to overcome an age-related decline in fertility. Cryopreservation of ovarian tissue is an option if egg cryopreservation is ruled out. More than 35 babies have been born so far with cryopreserved ovarian tissue in patients with cancer who have had a complete return of hormonal function, and fertility to baseline. Both egg and ovarian tissue cryopreservation might be ready for application to the preservation of fertility not only in patients with cancer but also in countering the increasing incidence of age-related decline in female fertility.
Article
Cryopreservation of eggs or ovarian tissue to preserve fertility for patients with cancer has been studied since 1994 with R G Gosden's paper describing restoration of fertility in oophorectomised sheep, and for decades previously by others in smaller mammals. Clinically this approach has shown great success. Many healthy children have been born from eggs cryopreserved with the Kuwayama egg vitrification technique for non-medical (social) indications, but until now very few patients with cancer have achieved pregnancy with cryopreserved eggs. Often, oncologists do not wish to delay cancer treatment while the patient goes through multiple ovarian stimulation cycles to retrieve eggs, and the patient can only start using the oocytes after full recovery from cancer. Ovarian stimulation and egg retrieval is not a barrier for patients without cancer who wish to delay childbearing, which makes oocyte cryopreservation increasingly popular to overcome an age-related decline in fertility. Cryopreservation of ovarian tissue is an option if egg cryopreservation is ruled out. More than 35 babies have been born so far with cryopreserved ovarian tissue in patients with cancer who have had a complete return of hormonal function, and fertility to baseline. Both egg and ovarian tissue cryopreservation might be ready for application to the preservation of fertility not only in patients with cancer but also in countering the increasing incidence of age-related decline in female fertility.
Article
Aim of the study: To induce puberty by transplantation of frozen/thawed ovarian tissue collected prior to gonadotoxic treatment for a cancer. Patients and methods: A 9-year-old girl with Ewing sarcoma had one ovary excised and cryopreserved prior to chemo- and radiotherapy. Functional activity of the remaining ovary was destroyed during treatment. Four and a half years later the girl remained pre-pubertal with postmenopausal levels of FSH. Two of ten pieces of frozen/thawed cortex were transplanted to the remaining ovary in order to stimulate puberty. Results: Four months after the transplantation FSH returned to low levels. During the following year puberty gradually progressed to Tanner stage B4 and P3 and regular menstrual cycles started. However, after 19 months the function of the graft ceased. Conclusions: We have shown for the first time in a girl treated for cancer that transplanted ovarian tissue can regain function and secrete estradiol in a sufficient amount to induce puberty. In addition, the majority of her ovarian tissue remains frozen with a possibility to support fertility in adult life.